Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers

Decreased expression of class III β-tubulin is associated with unfavourable prognosis in patients with malignant melanoma

(2016) Akira Shimizu et al.   MELANOMA RESEARCH

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

(2015) Wafik S. El-Deiry et al.   CANCER BIOLOGY & THERAPY

 III-Tubulin Regulates Breast Cancer Metastases to the Brain

(2015) D. Kanojia et al.   MOLECULAR CANCER THERAPEUTICS

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients

(2015) YING-CHUN XU et al.   ONCOLOGY REPORTS

A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer

(2014) Qiang Zhang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy

(2014) Zheng Li et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tubulin β-III: a novel immunohistochemical marker for intrahepatic peripheral cholangiocarcinoma

(2014) Yoh Zen et al.   HISTOPATHOLOGY

βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma

(2014) Alexander Quaas et al.   WORLD JOURNAL OF UROLOGY

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

(2013) Jun-Eul Hwang et al.   BMC CANCER

Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones

(2013) Dana M. Roque et al.   CANCER

Association between clinical pathology and multiple genes mRNA expression in Chinese patients with NSCLC

(2013) Gang Chen et al.   Journal of Cancer Research and Therapeutics

Lack of expression of TUBB3 characterizes both BCL2-positive and BCL2-negative follicular lymphoma

(2013) Alberto Zamò et al.   MODERN PATHOLOGY

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of  III-Tubulin Expression as a Predictive Marker

(2013) C. Saura et al.   ONCOLOGIST

Expression of β-tubulin III and Survivin in Advance Stage Breast Cancer Correlates with Chemotheraputic Effects of Docetaxel

(2012) Shao-Fei Yuan et al.   Asian Pacific Journal of Cancer Prevention

High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer

(2012) Yihong Wang et al.   Clinical Breast Cancer

High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers

(2012) Sarah Minner et al.   HISTOPATHOLOGY

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

(2012) Kyoichi Kaira et al.   International Journal of Clinical Oncology

Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy

(2012) Xue-Feng Leng et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

(2012) G. Levallet et al.   MOLECULAR CANCER THERAPEUTICS

Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel

(2012) D. M. Cittelly et al.   MOLECULAR CANCER THERAPEUTICS

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

(2012) Minkyu Jung et al.   PLoS One

Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance

(2012) Song Gao et al.   TUMOR BIOLOGY

Expression of β-tubulin isotypes in urothelial carcinoma of the bladder

(2012) Jung-Woo Choi et al.   WORLD JOURNAL OF UROLOGY

Class III  -Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial

(2011) A. C. Vilmar et al.   CLINICAL CANCER RESEARCH

Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and β III-Tubulin in Thymic Epithelial Tumors

(2011) Kyoichi Kaira et al.   Journal of Thoracic Oncology

Tumoral and tissue-specific expression of the major human β-tubulin isotypes

(2010) Luis J. Leandro-García et al.   Cytoskeleton

Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study

(2010) Lance C. Pagliaro et al.   JOURNAL OF CLINICAL ONCOLOGY

L1 is Highly Expressed in Tumors of the Nervous System: A Study of Over 8000 Human Tissues

(2010) Tamina Rawnaq et al.   JOURNAL OF SURGICAL RESEARCH

Beta-tubulin III expression in prostate cancer

(2010) Lars Egevad et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Class III  -tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma

(2009) Y. Koh et al.   ANNALS OF ONCOLOGY

Loss of Class III β-Tubulin Induced by Histone Deacetylation Is Associated with Chemosensitivity to Paclitaxel in Malignant Melanoma Cells

(2009) Kiyomi Akasaka et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Expression of ERCC1 and class IIIβ tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer

(2009) Satoshi Ikeda et al.   PATHOLOGY INTERNATIONAL

βIII-tubulin at the invasive margin of colorectal cancer: possible link to invasion

(2009) A. Portyanko et al.   VIRCHOWS ARCHIV

Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel

(2008) Koichi Azuma et al.   LUNG CANCER